WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010148519) METHODS AND THERAPIES FOR ALLEVIATING PAIN COMPRISING AN ULTRA LOW DOSE OF AN ALPHA 2 RECEPTOR ANTAGONIST
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/148519    International Application No.:    PCT/CA2010/001020
Publication Date: 29.12.2010 International Filing Date: 25.06.2010
IPC:
A61K 31/4178 (2006.01), A61K 31/4174 (2006.01), A61P 25/04 (2006.01)
Applicants: QUEEN'S UNIVERSITY AT KINGSTON [CA/--]; Kingston, Ontario K7L 3N6 (CA) (For All Designated States Except US).
JHAMANDAS, Khem [CA/CA]; (CA) (For US Only).
MILNE, Brian [CA/CA]; (CA) (For US Only).
CAHILL, Catherine M. [CA/CA]; (CA) (For US Only)
Inventors: JHAMANDAS, Khem; (CA).
MILNE, Brian; (CA).
CAHILL, Catherine M.; (CA)
Agent: SCRIBNER, Stephen J.; PARTEQ Innovations Room 1625, Biosciences Complex Queen's University at Kingston Kingston, Ontario K7L 3N6 (CA)
Priority Data:
61/220,282 25.06.2009 US
Title (EN) METHODS AND THERAPIES FOR ALLEVIATING PAIN COMPRISING AN ULTRA LOW DOSE OF AN ALPHA 2 RECEPTOR ANTAGONIST
(FR) PROCÉDÉS ET THÉRAPIES DESTINÉS À SOULAGER LA DOULEUR, UTILISANT UNE DOSE TRÈS FAIBLE D'UN ANTAGONISTE DU RÉCEPTEUR ALPHA-2
Abstract: front page image
(EN)A method for alleviating or delaying onset of pain in a subject via administration of an ultra low dose of alpha- 2 receptor antagonist which does not significantly block or inhibit alpha-2 receptor activity is provided. A non- selective alpha-2 receptor antagonist or a selective alpha- 2A receptor antagonist may be administered.
(FR)La présente invention concerne un procédé destiné à soulager une douleur ou à retarder son apparition chez un sujet par administration d'une dose très faible d'un antagoniste du récepteur alpha-2 qui ne bloque ni n'inhibe de manière significative l'activité du récepteur alpha-2. Un antagoniste non sélectif du récepteur alpha-2 ou un antagoniste sélectif du récepteur alpha-2A peut être administré.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)